NEWS
Tollys receives over €1.5 million deep tech financing from Bpifrance
Funds will further development of a new cancer immunotherapy: synthetic TLR3 agonist TL-532.
Three senior industry executives join the board of directors.
Tollys closes Series A financing of €2.3 million
Funds will further development of a new cancer immunotherapy: synthetic TLR3 agonist TL-532.
Three senior industry executives join the board of directors.
Tollys
A new dimension in immuno-oncology
Office
41 quai Fulchiron
69005 Lyon, FRANCE